New York, NY — The Cancer Research Institute (CRI) today announced the launch of its IGNITE Award—Inspiring Growth and Nurturing Independence Through Excellence—a bold new initiative designed to close a critical funding gap for early-career scientists in cancer immunology and immunotherapy.
The IGNITE Award provides up to five years of catalytic support, including two years of mentored postdoctoral funding, followed by three years of independent faculty support, paired with a formal co-investment from host institutions. This dual commitment maximizes the likelihood of long-term success for scientists embarking on independent research careers.
Early-career scientists are facing unprecedented headwinds—fewer jobs, tighter institutional budgets, and shrinking federal support. “If we don’t protect this next generation of researchers, we risk losing the very people who will drive the discoveries of tomorrow,” said E. John Wherry, PhD, an associate director of CRI’s Scientific Advisory Council and co-chair of the IGNITE Award selection committee. “IGNITE fills this gap and ensures that the best and brightest can thrive.”
In the past year alone, CRI has invested $33M to fund 68 new grants and fellowships across 41 institutions worldwide, empowering researchers whose discoveries are shaping the future of cancer treatment. The IGNITE Award builds on that legacy, expanding CRI’s long-standing commitment to scientific training and support. As Lewis L. Lanier, PhD, co-chair of the IGNITE Award selection committee, explained, “For decades, CRI has been a steadfast pillar supporting the field of cancer immunotherapy. With IGNITE, CRI continues that legacy, ensuring the next generation of researchers has the foundation to thrive.”
For CRI, the launch of IGNITE marks both a continuation and an evolution. “IGNITE is about more than just funding—it’s about fueling possibility,” said Alicia Zhou, PhD, CEO of the CRI. “We’re betting on the next generation of leaders in cancer immunotherapy, giving them the runway to turn bold ideas into breakthroughs that will change how we treat, and ultimately defeat, cancer.”
Applications for the inaugural IGNITE Award are due January 9, 2026.
For more information about eligibility and how to apply, visit cancerresearch.org/IGNITE.
